| Title |
Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70
|
|---|---|
| Published in |
Biologics: Targets & Therapy, December 2012
|
| DOI | 10.2147/btt.s36707 |
| Pubmed ID | |
| Authors |
Michelle E Orme, Katherine S MacGilchrist, Stephen Mitchell, Dean Spurden, Alex Bird |
| Abstract |
Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritis patients with suboptimal response or intolerance to conventional DMARDs. The objective of this systematic review and meta-analysis was to compare the relative efficacy of EU-licensed bDMARD combination therapy or monotherapy for patients intolerant of or contraindicated to continued methotrexate. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| Ecuador | 1 | 1% |
| Brazil | 1 | 1% |
| Belgium | 1 | 1% |
| Spain | 1 | 1% |
| Japan | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 71 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 23% |
| Student > Master | 13 | 17% |
| Student > Ph. D. Student | 7 | 9% |
| Other | 6 | 8% |
| Student > Postgraduate | 6 | 8% |
| Other | 19 | 24% |
| Unknown | 9 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 53% |
| Agricultural and Biological Sciences | 7 | 9% |
| Nursing and Health Professions | 3 | 4% |
| Economics, Econometrics and Finance | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 11 | 14% |
| Unknown | 11 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2018.
All research outputs
#4,877,762
of 25,540,105 outputs
Outputs from Biologics: Targets & Therapy
#57
of 285 outputs
Outputs of similar age
#45,877
of 286,509 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 7 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,509 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them